Present study demonstrates that VAT, but not SAT, is involved in the development of late obesity insulin resistance, and PPAR-γ agonist pioglitazone suppresses obesity related diabetes in mice during the early and late phases by enhancing the expressions of PPAR-γ and CIDEC and ultimately decreasing the level of blood sugar. Here, PPARG is linked to obesity disorder.